MVR.F · Medivir AB (publ)

-

Please sign in to comment on MVR.F

1 Comment

Admin

3 years, 7 months ago

Medivir AB (publ) is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.

From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.2.

Medivir AB (publ)'s total revenue sank by 22.8% to $1M since the same quarter in the previous year.

Its net income has increased by 114.4% to $5M since the same quarter in the previous year.

Finally, its free cash flow grew by 80.7% to $-5M since the same quarter in the previous year.

Based on the above factors, Medivir AB (publ) gets an overall score of 3/5.

ISIN	SE0000273294
CurrencyCode	EUR
Exchange	F
Industry	Biotechnology
Sector	Healthcare

Market Cap	38M
Dividend Yield	0.0%
Target Price	None
PE Ratio	None
Beta	0.37

ABOUT

Medivir AB (publ)

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

MVR.F · Medivir AB (publ)

-

Medivir AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Medivir AB (publ) using a moving average strategy